高级搜索

调强放疗同步化疗治疗宫颈癌血液学毒性相关因素分析

唐滟, 袁亚维

唐滟, 袁亚维. 调强放疗同步化疗治疗宫颈癌血液学毒性相关因素分析[J]. 肿瘤防治研究, 2016, 43(4): 277-281. DOI: 10.3971/j.issn.1000-8578.2016.04.008
引用本文: 唐滟, 袁亚维. 调强放疗同步化疗治疗宫颈癌血液学毒性相关因素分析[J]. 肿瘤防治研究, 2016, 43(4): 277-281. DOI: 10.3971/j.issn.1000-8578.2016.04.008
shu
TANG Yan, YUAN Yawei. Risk Factors Associated with Hematologic Toxicity in Concurrent Chemoradiotherapy and IMRT for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 277-281. DOI: 10.3971/j.issn.1000-8578.2016.04.008
Citation: TANG Yan, YUAN Yawei. Risk Factors Associated with Hematologic Toxicity in Concurrent Chemoradiotherapy and IMRT for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 277-281. DOI: 10.3971/j.issn.1000-8578.2016.04.008
shu

调强放疗同步化疗治疗宫颈癌血液学毒性相关因素分析

  • 1. 510515 广州，南方医科大学南方医院放疗科；2. 411100 湘潭，湘潭市中心医院放疗科

详细信息
    作者简介:

    唐滟（1979-），女，硕士，副主任医师，主要从事肿瘤放射治疗的基础及临床研究

    通讯作者:

    袁亚维，E -mail: yuanyw66@aliyun.com

  • 中图分类号: R737.3

Risk Factors Associated with Hematologic Toxicity in Concurrent Chemoradiotherapy and IMRT for Cervical Cancer

  • 1. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; 2. Department of Radiation Oncology, Xiangtan Central Hospital, Xiangtan 411100, China

HTML全文

    摘要
  • 摘要: 目的 探讨调强放疗同步化疗治疗宫颈癌的过程中出现严重血液学毒性的相关因素。方法 回顾性分析126例调强放疗同步化疗的宫颈癌患者资料，对同步放化疗期间可能与严重血液学毒性相关的因素进行单因素和多因素分析。结果 单因素分析显示严重血液学毒性的发生与治疗前肌酐水平、放疗前是否接受化疗及是否有骨髓抑制、骨盆骨髓平均剂量、V20、V40及V50有关（P<0.05）。多因素分析显示骨盆骨髓平均剂量（OR: 1.004, 95%CI: 1.002~1.007）、V40（<41% vs. ≥41%, OR: 0.040, 95%CI: 0.007~0.235）、V50 （<9% vs. ≥ 9%, OR: 0.040, 95%CI: 0.011~0.152）和治疗前肌酐水平（<65 μmol/L vs.≥65 μmol/L, OR: 0.116, 95%CI: 0.030~0.441）与3~4级血液学毒性相关。结论 治疗前肌酐<65 μmol/L、V40<41%和V50<9%是宫颈癌患者同步放化疗期间3~4级血液学毒性发生率降低的相关因素。骨盆骨髓平均剂量越高，血液学毒性发生率增高。治疗前评估肾功能水平，严格控制骨盆骨髓的放疗照射体积及剂量，能减少宫颈癌患者血液学毒性发生，是顺利完成调强放疗同步化疗的保障。

     

    Abstract: Objective To investigate the risk factors associated with hematologic toxicity (HT) in the treatment of concurrent chemotherapy and intensity modulated radiotherapy (IMRT) for cervical cancer. Methods We analyzed 126 cervical cancer patients treated with concurrent chemotherapy and pelvic IMRT. Univariate and multivariate analysis were performed to evaluate the known and hypothesized factors associated with HT. Results Univariate analysis showed that mean dose to pelvic bone marrow (PBM), the volume of PBM receiving 20, 40, and 50 Gy (V20, V40, and V50), initial serum creatinine, chemotherapy before concurrent chemoradiotherapy (CCRT), and BM suppression before CCRT were associated with the incidence of severe HT (P<0.05). By multivariate analysis, the mean dose to PBM (OR: 1.004, 95%CI: 1.002-1.007),V40 (<41% vs. ≥41%, OR: 0.040, 95%CI: 0.007-0.235), V50 (<9% vs. ≥ 9%, OR: 0.040, 95%CI: 0.011-0.152), and initial serum creatinine (<65μmol/L vs.≥65μmol/L, OR: 0.116, 95%CI: 0.030-0.441) were the factors significantly correlated with grades 3~4 HT. Conclusion Initial serum creatinine <65μmol/L, V40<41%, and V50<9% are the factors associated with low incidence of grades 3~4 HT in the treatment of concurrent chemotherapy and IMRT for cervical cancer patients. As the mean dose to bone marrow increases, the incidence of grades 3~4 HT grows. Evaluating initial serum creatinine is needed before CCRT. Strictly controlling the irradiated volume of PBM and the dose to PBM treated with IMRT which can reduce the incidence of HT is warranted in cervical patients receiving CCRT.

     

    • HTML全文
    • 参考文献(20)
  • [1] Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma[J]. N Engl J Med, 1999, 340 (15): 1154-61.
    [2] Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer[J]. N Engl J Med, 1999, 340 (15): 11 37-43.
    [3] Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high risk early stage cancer of the cervix[J]. J Clin Oncol, 2000, 18 (8): 1606-13.
    [4] Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage ⅡB-ⅣA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study[J]. Clin Oncol, 19 99, 17(5): 1339-48.
    [5] Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J]. N Engl J Med, 1999, 340(15): 1144-53.
    [6] Vale C, Tierney JF, Stewart LA, et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials[J]. J Clin Oncol, 2008, 26(35): 5802-12.
    [7] Tian W, Zhang Y, Lin L, et al. Evaluation of clinical efficiency of neoadjuvant chemotherapy in the treatment of patients with cervical carcinoma[J]. Zhong Liu Ji Chu Yu Lin Chuang, 2010, 23 (1) : 30-1.[田卫红, 张延曙, 林丽红,等. 宫颈癌术前新辅助化疗 的临床观察[J]. 肿瘤基础与临床, 2010, 23(1): 30-1.]
    [8] Pang HW, Sun XY, Yang B, et al. Relationship between bladder and rectum volume and its absorbed dose of radical intensity modulated radiotherapy on cervical cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2016, 43(1): 63-6.[庞皓文, 孙小杨, 杨波, 等. 宫颈 癌根治性调强放疗期间膀胱直肠体积与其吸收剂量的关系[J]. 肿瘤防治研究, 2016, 43(1): 63-6.]
    [9] Hu QC. The status of concurrent chemotherapy for cervical cancer[J]. Zhong Liu Ji Chu Yu Lin Chuang, 2011, 24 (5): 45 3-5.[胡群超.宫颈癌同步放化疗研究现状[J].肿瘤基础与临 床, 2011, 24(5):453-5.]
    [10] Hui B, Zhang Y, Shi F, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy[J]. Int J Gynecol Cancer, 2014, 24(9): 1648-52.
    [11] Chen CC, Wang L, Lin JC, et al. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy[J]. J Formos Med Assoc, 2015, 114(3): 231-7.
    [12] Klopp AH, Moughan J, Portelance L, et al. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer[J]. Int J Radiat Oncol Biol Phys, 2013, 86(1): 83 -90.
    [13] Albuquerque K, Giangreco D, Morrison C, et al. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT[J]. Int J Radiat Oncol Biol Phys, 2011, 79(4): 10 43-7.
    [14] Parker K, Gallop-Evans E, Hanna L, et al. Five years, experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution[J]. Int J Radiat Oncol Biol Phys, 2009, 74 (1): 140-6.
    [15] Mauch P, Constine L, Greenberger J, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5): 13 19-39.
    [16] Rose BS, Aydogan B, Liang Y, et al. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys, 2011, 79(3): 800-7.
    [17] Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated Pelvic radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2006, 66(5): 13 56-65.
    [18] Mell LK, Schomas DA, Salama JK, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2008, 70(5): 1431-7.
    [19] Mell LK, Tiryaki H, Ahn KH, et al. Dosimetric comparison of bone marrow sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 71(5): 1504-10.
    [20] Brixey CJ, Roeske JC, Lujan AE, et al. Impact of intensity modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies[J]. Int J Radiat Oncol Biol Phys, 20 02, 54(5): 1388-96.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1280
  • HTML全文浏览量:  322
  • PDF下载量:  401
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-04-08
  • 修回日期:  2015-11-19
  • 刊出日期:  2016-04-24

目录

摘要
HTML全文
    参考文献(20)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11646529 今日访问：13878

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭